Detalles de la búsqueda
1.
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Target Oncol;
2024 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38613731
2.
Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab.
Cancers (Basel);
16(7)2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38611087
3.
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
Br J Cancer;
2024 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38519705
4.
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Cancer Sci;
115(4): 1296-1305, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402853
5.
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis.
Ann Am Thorac Soc;
21(4): 635-643, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38364204
6.
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
Invest New Drugs;
42(1): 136-144, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38300341
7.
Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
J Thorac Oncol;
19(2): 337-343, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37943237
8.
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
JAMA Netw Open;
6(12): e2347700, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38100106
9.
Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L).
JTO Clin Res Rep;
4(10): 100569, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37822699
10.
Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors.
Cancer Med;
12(19): 19471-19479, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37712645
11.
Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Lung Cancer;
184: 107351, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37639819
12.
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
J Immunother Cancer;
11(7)2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37433717
13.
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
Cancer Sci;
114(8): 3330-3341, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37183528
14.
Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426.
Transl Cancer Res;
12(4): 873-886, 2023 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37180670
15.
Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Thorac Cancer;
14(15): 1362-1367, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37037511
16.
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer.
Sci Rep;
13(1): 3698, 2023 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36878936
17.
Proton Beam Therapy as a Curative Treatment for a Young Case of Unresectable Tracheal Adenoid Cystic Carcinoma.
Intern Med;
62(19): 2877-2881, 2023 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36792199
18.
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
BMC Cancer;
23(1): 6, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36597021
19.
Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Thorac Cancer;
14(1): 73-80, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36377039
20.
A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.
Thorac Cancer;
13(20): 2911-2914, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36073307